The Senate hearing dealing with FDA user fees covered much of the predictable ground, but Sen. Richard Burr (R-N.C.), a frequent critic of the agency, gave voice to the prospect that the user fee-authorizing legislation would incorporate a clawback mechanism for appropriations should the agency fail to meet the goals of the next set of user fee agreements.